Alnylam Lowers 2026 Outlook As Second-Line Amvuttra Demand Normalizes, Stock Tanks - Alnylam Pharmaceutic
Alnylam reported Q2 adjusted EPS of $1.84, above $1.55 consensus, while revenue rose 67% to $1.291B, below $1.323B. Amvuttra and Onpattro net product revenues were $1.012B and $18M. The company cut 2026 sales guidance to $5.275B-$5.725B from $5.30B-$5.80B, citing normalized second-line Amvuttra demand. Shares fell 29% to $202.74.
How this was made
The 30-second read
Why it matters
The key new information is the full-year 2026 sales guidance reduction driven by normalization of second-line volume after earlier pent-up demand, alongside a large negative stock reaction. The article also flags ongoing clinical-trial scrutiny for ATTR-CM developers but includes management’s reaffirmation of confidence in nucrisiran.
Market read
Traders can update 2026 revenue expectations and risk premia for ALNY based on the explicit guidance cut and the stated demand normalization mechanism.
What to watch
The company also reaffirms confidence in its Phase 3 nucrisiran/TRITON-CM program, which could limit long-term downside if trial risk is perceived as contained.
Background
Alnylam’s Amvuttra and Onpattro are gene-silencing therapies for hATTR amyloidosis, with 2026 guidance tied to TTR product sales in the ATTR-CM market.
Ticker impact
Alnylam cut its full-year 2026 TTR product sales guidance to $5.275B-$5.725B as Amvuttra second-line growth normalizes.
Near-term downside bias likely as traders weigh slower 2026 growth against prior expectations.
The article discloses a specific 2026 sales guidance reduction plus reported Q2 results and notes the stock is at a new 52-week low, indicating immediate market repricing.
Market effects
ATTR-CM gene-silencing peers may face read-across risk if investors generalize “second-line normalization” to the category.
Limited direct regional spillover; primary impact is on US-listed biotech sentiment.
Could affect global investor positioning in hATTR amyloidosis treatment demand expectations.
Counterpoint
The guidance cut may reflect timing and normalization after pent-up demand, not a structural impairment of the Amvuttra franchise.
Key entities
- companyAlnylam Pharmaceuticals
Lowered 2026 TTR product sales guidance and reported Q2 results; stock fell sharply.
- productAmvuttra
Second-line ATTR-CM therapy whose growth is described as normalizing after pent-up demand.
- productOnpattro
Another hATTR gene-silencing therapy with Q2 net product revenues disclosed.
- clinical_programnucrisiran (TRITON-CM)
Phase 3 program where management reaffirms confidence despite questions raised by an Ionis trial failure.
